> Review 2013 > TCTAP Daily Newspaper


April 25 (Thu.), 2013
Late Breaking Clinical Trials
Highlights from the "Late Breaking Clinical Trials" meeting will be held 9:30 AM - 10:25 AM at the Main Arena, Level 3. Brand new data from this
year will be presented for the first time. These sessions provide notable exposure and recognition for studies likely to significantly affect clinical practice. Evaluation of the presentation in the Late Breaking Clinical Trial sessions will be based on the impact and novelty of the research. Late Breaking Clinical Trials at TCTAP 2013 covers information on the latest scientific breakthroughs on five featured topics including drug-eluting stents, acute coronary syndrome, diabetes mellitus, transcatheter aortic valve implantation, and functional angioplasty.
- Comparison of Platinum Chromium Versus Cobalt Chromium........
2013 TCTAP Wrap-up Interview
Fractional flow reserve (FFR) is a reliable functional index for epicardial coronary stenosis. It has been previously reported that deferring lesions of intermediate severity
at angiography with a FFR 0.75-0.80 has a good clinical follow-up. Especially in multivessel disease, FFR-guided PCI led to better clinical outcome compared with angioguided PCI. Evidences support that physiologic assessment is essential to make a
decision on how to treat. Recent studies validated the optimal MLA threshold predicting
FFR. Although the MLA cut-offs are ranged from 2.0-3.0 mm, they suggested that there is no MLA cut-off showing accuracy higher than 70%. Even in subgroupspecific MLA cut-off (according to vessel size, lesion segment, LAD or non-LAD), their predictabilities were disappointing.
Because MLA is only one of the multiple determinants of FFR, it cannot predict FFR accurately. Thus, the decision for treatment should be based on the functional lesion assessment. With regard to stent optimization, IVUS criteria have been well established and.......
Acute Coronary Syndrome: Evolving Issues

Acute Chest Pain in the Emergency Room
Acute myocardial infarction (AMI) represents the most urgent form of acute coronary
syndrome and requires immediate diagnosis and treatment for improved outcomes.
For patients presenting with STsegment elevation MI (STEMI), the diagnosis is rather apparent from the combination of clinical symptoms and EKG changes. However, for
those with non- STEMI, the diagnosis may not be simple, especially when the EKG is not
diagnostic and /or the symptoms are atypical.
For these patients, it is paramount to make the correct diagnosis with the aid of cardiac biomarkers. Novel hs-troponin could facilitate the prompt and correct diagnosis of non-STEMI and prevent unwarranted discharge or delay of treatment for patients at high risk for ischemic complications. An advantage of hs-troponin includes the ability to detect extremely minute amounts of cardiac troponin levels and thus, enables both early diagnosis of myocardial injury and identification of small myocardial infarction.
Recent studies........

PROGRAM
Scientific Program
Competition Session
Satellite Symposia		 CASES & ABSTRACTS
Accepted Cases
Accepted Abstracts		 REVIEW 2013
Quick Reveiw
Wrap-up Interview
Daily Newspaper
TCTAP Gallery
Factoid		 ABOUT
About TCTAP
Board Members
- Course Directors
- Course Co-Directors
- Scientific Committee
- Advisory Committee		 FACULTY
International Faculty
- Invited Faculty
- Faculty of the Year
Korean Faculty
- Invited Faculty
- Faculty of the Year